Janux Therapeutics Ratios and Metrics

Market cap in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Year	Current	2023	2022	2021	2020	2019
Market Capitalization	2,774	495	549	821	-	-
Market Cap Growth	-	-9.72%	-33.17%	-	-	-
Enterprise Value	2,146	175	246	445	-8	3
PE Ratio	-34.99	-8.50	-8.70	-25.13	-	-
PS Ratio	380.68	61.29	63.71	225.73	-	-
PB Ratio	4.23	1.44	1.71	2.24	-	-
P/FCF Ratio	-36.52	-9.45	-11.11	-44.48	-	-
P/OCF Ratio	-37.77	-9.80	-12.78	-48.36	-	-
EV/Sales Ratio	294.44	21.66	28.59	122.47	-	-
EV/EBITDA Ratio	-24.58	-3.11	-3.96	-13.68	1.19	-0.89
EV/EBIT Ratio	-23.68	-3.00	-3.90	-13.63	1.19	-0.89
EV/FCF Ratio	-24.72	-3.34	-4.99	-24.13	1.79	-0.87
Debt / Equity Ratio	0.04	0.07	0.08	0.00	-	-0.50
Debt / EBITDA Ratio	-0.45	-0.44	-0.41	-0.01	-	-1.06
Debt / FCF Ratio	-0.45	-0.47	-0.51	-0.01	-	-1.04
Quick Ratio	61.56	26.46	19.86	29.36	4.97	0.14
Current Ratio	62.09	26.80	20.14	29.46	5.05	0.14
Asset Turnover	0.02	0.02	0.02	0.01	0	-
Interest Coverage	-	-	-	-	-31.93	-16.18
Return on Equity (ROE)	-13.50%	-17.90%	-18.70%	-11.80%	60.10%	-
Return on Assets (ROA)	-12.40%	-16.00%	-16.90%	-10.50%	-80.30%	-
Return on Capital (ROIC)	-10.72%	-19.78%	-19.39%	-8.98%	33.09%	95.61%
Earnings Yield	-2.00%	-11.77%	-11.49%	-3.98%	-	-
FCF Yield	-1.92%	-10.58%	-9.00%	-2.25%	-	-
Buyback Yield / Dilution	-17.45%	-6.14%	-76.24%	-2471.20%	-36.71%	-
Total Shareholder Return	-17.45%	-6.14%	-76.24%	-2471.20%	-36.71%	-

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).